Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.

N, Lukan; P, Ströbel; A, Willer; M, Kripp; D, Dinter; S, Mai; A, Hochhaus; RD, Hofheinz

doi:10.1159/000259615

Public

Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.

Shared by NobleBlocks on Nov 17, 2009 • 12:00 AM UTC

Authors:

Lukan N

Ströbel P

Willer A

Abstract

Background No standard chemotherapy regimen can be defined for patients with metastatic squamous cell carcinoma of the anus due to the low incidence of this disease and the high cure rate of localized tumors. Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutat...

Discussions